N-acetylcysteine for Root Canal Treatment of Necrotic Teeth With Apical Periodontitis (NAC)

Alexandria University

Status and phase: Active, not recruiting; Phase 2

Conditions: Apical Periodontitis

Treatments: Drug: N-Acetylcysteine (NAC); Drug: Calcium hydroxide (Ca(OH)₂)

Study type: Interventional

Funder types: Other

Identifiers

NCT07262554

PACTR202511513893768 (Registry Identifier)

9258326

Details and patient eligibility

About

A randomized controlled trial comparing the postoperative pain intensity, periapical biomarkers level, and periapical healing in patients with necrotic mature teeth and apical periodontitis treated with N-acetylcysteine (NAC), as an intracanal and adjunctive systemic medication, versus calcium hydroxide (Ca(OH)₂) intracanal medication alone.

Enrollment: 40 estimated patients

Sex: All

Ages: 16 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Mature necrotic teeth.
• Radiographic evidence of periapical bone loss.
• Teeth that require primary endodontic treatment.
• Restorable teeth.

Exclusion criteria

• Immature teeth
• Teeth that had been previously accessed or endodontically treated.
• Teeth with periodontal pockets deeper than 4 mm.
• Patients with acute apical abscess.
• Patients with systemic diseases.
• Pregnant females.
• Patients who received antibiotic therapy within the past month.
• Patient on analgesics.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

40 participants in 2 patient groups

Calcium hydroxide (Ca(OH)₂)

Active Comparator group

Description:

UltraCal XS calcium hydroxide (Ca(OH)₂) intracanal medication for 7 days

Treatment:

Drug: Calcium hydroxide (Ca(OH)₂)

N-acetylcysteine (NAC)

Experimental group

Description:

N-acetylcysteine (NAC) intracanal medication for 7 days and 600 mg/day oral NAC for 21 days

Treatment:

Drug: N-Acetylcysteine (NAC)